A Delaware federal judge has allowed Amgen Inc. to pursue enhanced damages in its patent infringement dispute with a rival drugmaker, the latest development to a case with billions of dollars on the line.
U.S. District Judge Sue L. Robinson of the District of Delaware on Wednesday granted Amgen’s motion to amend a Jan. 3 memorandum opinion to include an award of supplemental damages, as well as enhanced damages on top of those.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]